 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
3388 News |  |
| «12...3233343536373839404142...4849» |
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: Epidemiology and genomic characterization. (Pubmed Central) - Nov 12, 2020
Our results showed that incidence of ceftazidime/avibactam resistance emerged in KCP-Kp strains independently from previous antimicrobial exposure. Resistance to ceftazidime/avibactam was associated with mutations within the bla gene or porin deficiency associated with higher bla copy number and is also related to the meropenem/vaborbactam resistance.
- | Journal: Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria. (Pubmed Central) - Nov 5, 2020
Other agents showing in vitro activity against MBL-GNB are currently in clinical development (e.g., cefepime/taniborbactam, LYS228, cefepime/zidebactam) that could be an important addition to our future armamentarium for severe MBL-GNB infections. Nonetheless, we should not discontinue our efforts to optimize the use of non-β-lactams agents, since they could remain an essential last-resort or alternative option in selected cases.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Biomarker, Clinical, Journal: Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. (Pubmed Central) - Nov 2, 2020
Time to appropriate antibiotic therapy is an independent predictor of 30-day mortality in patients with KPC-Kp BSI. Appropriate antibiotic therapy should begin within 24 h from the collection of BC.
- || gentamicin sulfate / Generic mfg.
Clinical, Journal: Population structure of KPC carbapenemase-producing Klebsiella pneumoniae in a long-term acute-care rehabilitation facility: identification of a new lineage of clonal group 101, associated with local hyperendemicity. (Pubmed Central) - Nov 2, 2020
All the CG101 isolates had a capsule locus type KL17...Analysing WGS data, we were able to ascertain the common origin of some isolates imported from other hospitals, and to track several clusters of in-LTACRF cross-transmissions. The results revealed that, in peculiar epidemiological settings such as LTACRF, new KPC-Kp clones different from those prevailing in acute-care hospitals and associated with uncommon resistance and virulence determinants can successfully emerge and disseminate.
- | aztreonam-avibactam (PF-06947387) / Pfizer, AbbVie, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019. (Pubmed Central) - Nov 1, 2020
Our study revealed significant antimicrobial resistance among the CRE isolates against some commonly used antibiotics in three secondary Chinese hospitals. ATM/AVI exhibited potent activity against CRE isolates, including double carbapenemase-producing isolates, whereas CAZ/AVI was active against all KPC producers.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Somehow missed these new guidelines. So helpful. MDR Steno on biofilms is a big problem in our lung transplant patients. We've treated a number with CAZ-AVI + ATM after showing in vitro synergy. Interested to hear your thoughts on the clinical efficacy of this regimen (Twitter) - Oct 30, 2020
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Zerbaxa برای اولین بار در 19 دسامبر 2014 تایید شد و توسط Merck و Co. تولید شده است. Avycaz به عنوان تزریق داخل وریدی هر 8 ساعت داده می شود. تنظیمات لازم در بیماران با اختلالات کلیوی ضروری است.. @merck #dizziness اجازه ورد داروهای خارجی (Twitter) - Oct 29, 2020
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Fauci probably couldn’t tell you differences between Zerbaxa and Avycaz (Twitter) - Oct 25, 2020
- ||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, La Jolla Pharma, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical: Resistance rates have been steadily increasing at our institution for FQs and TMP/SMX. We’ve been moving towards using Eravacycline for a lot of Stenotrophomonas cases. Specifically for invasive infection, would consider the combination of avycaz and aztreonam (Twitter) - Oct 23, 2020
- |||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, PK/PD data: 3/10: Poster 1298 - Population pharmacokinetics of ceftazidime-avibactam among critically-ill patients with and without receipt of continuous renal-replacement therapy by @erinmccreary @ryankshields @yohei_doi https://t.co/otX2eROP8c #IDWeek2020 (Twitter) - Oct 21, 2020
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
I'm a little concerned about last sentence "Ceftazidime/avibactam is ... active against carbapenem resistant microorganisms, and should be used judiciously to preserve its activity against these." I thought of it as a drug to use if carbapenems fail not vise versa🧐 (Twitter) - Oct 16, 2020
- | Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Evaluation of two commercial methods for rapid detection of the carbapenemase-producing Klebsiella pneumoniae. (Pubmed Central) - Oct 15, 2020
However, Rapidec Carba NP with weak hydrolysis activity for OXA-48 like might be used in regions where OXA-48 is not prevalent. The additional advantage of NG-Test Carba 5 is that it specifically detects carbapenemases giving way to threat-related infections with an effective drug such as ceftazidime-avibactam or meropenem- vaborbactam.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Review: NEW 🔥🔥 #AAC @ASMicrobiology @burcucella @adm_stewart @padstamundo @davidantibiotic Is ceftazidime/avibactam an option for serious infections due to ESBL and AmpC producing Enterobacterales?: a systematic review and meta-analysis. #IDTwitter @DrToddLee https://t.co/kLaBJbCjSe (Twitter) - Oct 12, 2020
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Efficacy of the Recommended Ceftazidime/Avibactam Dose in Treating Carbapenem-Resistant Enterobacteriaceae in Critically Ill Patients Using Renal Replacement Therapies (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3016;
The CEF/AVI recommended dose could achieve uncertain clinical outcomes. Pharmacokinetics and pharmacodynamics studies are urgently needed to determine the adequacy of CEF/AVI dosing in this population
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36). (Pubmed Central) - Oct 10, 2020
Pharmacokinetics and pharmacodynamics studies are urgently needed to determine the adequacy of CEF/AVI dosing in this population No abstract available
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Successful treatment of septic shock due to NDM1-producing K. pneumoniae using ceftazidime-avibactam combined with aztreonam in solid organ transplant recipients: report of 2 cases. (Pubmed Central) - Oct 10, 2020
No abstract available No abstract available
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Combination therapy: Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis. (Pubmed Central) - Oct 10, 2020
This work suggests a lack of improved in vitro bactericidal activity or in vivo efficacy when polymyxin B is combined with ceftazidime-avibactam against KPC-producing K. pneumoniae. This combination should be avoided in lieu of ceftazidime-avibactam alone or other potentially more efficacious, less toxic combination regimens.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] ANTIMICROBIAL ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COMPARATOR AGENTS AGAINST PSEUDOMONAS AERUGINOSA AND ENTEROBACTERALES CAUSING PNEUMONIA IN CYSTIC FIBROSIS PATIENTS () - Oct 7, 2020 - Abstract #NACFC2020NACFC_721;
CAZ-AVI exhibited potent and broad spectrum activity against PSA (96.0%S) and ENT (100.0%S) isolated from CF patients worldwide and retained good activity against isolates resistant to other antimicrobials including MDR organisms. CAZ-AVI represents a valuable option to treat CF patients with pneumonia.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical: Yes. We have used both caz-avi and imi-rele (Separate cases, not in combo with each other) for MDR abscessus subspecies abscessus on multiple occasions. We have an NTM clinic with ~80 regular cases and new ones each day on the inpatient side. (Twitter) - Oct 7, 2020
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Trial completion date, Trial primary completion date: Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia (clinicaltrials.gov) - Oct 4, 2020
P1, N=32, Recruiting, Sponsor: Pfizer
CAZ-AVI represents a valuable option to treat CF patients with pneumonia. Trial completion date: Jul 2021 --> Nov 2021 | Trial primary completion date: Jul 2021 --> Nov 2021
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Cost-Effectiveness Analysis Ceftazidime/Avibactam for the Treatment of Hospital Acquired Pneumonia and Ventilator Associated Pneumonia Due to Carbapenem Resistant Klebsiella Pneumonia in Argentina () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1901;
Deterministic and probabilistic sensitivity analyses show that results are robust to all scenarios. CONCLUSIONS The cost-effective analysis has demonstrated that CAZ-AVI appears to be a dominant treatment in patients with hospital acquired pneumonia and ventilator associated pneumonia (HAP/VAP) due to Carbapenem resistant Klebsiella Pneumonia in Argentina.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Cost-Effectiveness Analysis of Ceftazidime/Avibactam for the Treatment of Intrabdominal Infection Due to Carbapenem Resistant Enterobactereas in Argentina () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_909;
Deterministic and probabilistic sensitivity analyses show that results are robust to all scenarios. CONCLUSIONS The cost-effective analysis has demonstrated that CAZ-AVI appears to be a dominant treatment in patients with intraabdominal infections due to carbapenem resistant Enterobactereas in Argentina.
- | rifampicin / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Sequence type-258 carbapenem-resistant Klebsiella pneumoniae isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. (Pubmed Central) - Oct 2, 2020
Mutational frequencies did not differ between clade II and I isolates. Ceftazidime-avibactam resistance among ST258, clade II K. pneumoniae is most likely a reflection of our hospital's ecology.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), meropenem / Generic mfg., Daewon Pharmaceutical, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). (Pubmed Central) - Oct 2, 2020
Among ESBL-producing Enterobacterales (excluding carbapenemase-producing), susceptibility rates for ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem were 100.0%, 84.1%, and 98.9%, respectively. Ceftazidime-avibactam and ceftolozane-tazobactam were very active against P. aeruginosa (n = 2215) and exhibited similar susceptibility rates (96.0% and 95.9% susceptible, respectively), including against meropenem-nonsusceptible (87.2% and 87.3% susceptible, respectively) and MDR (83.5% and 83.7% susceptible, respectively) isolates.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study. (Pubmed Central) - Oct 1, 2020
Some studies reported experiences for the treatment of MDR-GNB infections in patients with hematological malignancies or specifically in Pseudomonas aeruginosa infections. We report our clinical single-center experience regarding the real-life use of ceftolozane/tazobactam and ceftazidime/avibactam to treat serious and complicated infections due to MDR-GNB and carbapenem-resistant Enterobacterales (CRE), with particular regard given to intra-abdominal and urinary tract infections and sepsis.
- || ciprofloxacin / Generic mfg.
Clinical, Journal: Clinical and Microbiological Characteristics of Community-Onset Carbapenem-Resistant Enterobacteriaceae Isolates. (Pubmed Central) - Sep 30, 2020
Community-onset CRE is not rare, and the dissemination of E. coli was sporadic while K. pneumoniae was clonal spread with similar STs as HA-CRE. Active surveillance of CRE in the community setting is in demand.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. (Pubmed Central) - Sep 27, 2020
Non-susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam was largely due to the production of ESBL and VIM enzymes. Ceftazidime/avibactam and ceftolozane/tazobactam are possible options for some patients with MDR P. aeruginosa in Qatar.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Colistin is tough. Even assaying it is a pain. Many papers by Li and Nation. The poly guidelines highlight these. Tige. Not much. Check out FDA submission materials for work by company. Caz.avi. unsure... For clin outcomes... In public domain. Good luck! (Twitter) - Sep 25, 2020
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam. (Pubmed Central) - Sep 25, 2020
This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Publication with caz-avi concentrations: https://t.co/opUXUiHqI9 Tol-Taz only has a rat study on file with Merck that actually showed poor concentration with single dose ceftolozane, but used in case report: https://t.co/DCTliOBDfh (Twitter) - Sep 23, 2020
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. (Pubmed Central) - Sep 21, 2020
Ceftazidime/avibactam is a valuable antibiotic against MDR and carbapenem-resistant Enterobacterales. Based on time-kill kinetics as well as an in vivo infection model we postulate a combination therapy of ceftazidime/avibactam and imipenem as a strategy to prevent the development of ceftazidime/avibactam resistance in KPC-producing Enterobacterales in vivo.
- | imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Journal: Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. (Pubmed Central) - Sep 19, 2020
Based on time-kill kinetics as well as an in vivo infection model we postulate a combination therapy of ceftazidime/avibactam and imipenem as a strategy to prevent the development of ceftazidime/avibactam resistance in KPC-producing Enterobacterales in vivo. Imipenem/relebactam was the most potent agent tested against CPE in this study and may be a useful addition to the antimicrobial armamentarium to treat infections caused by these pathogens.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. (Pubmed Central) - Sep 19, 2020
Imipenem/relebactam was the most potent agent tested against CPE in this study and may be a useful addition to the antimicrobial armamentarium to treat infections caused by these pathogens. O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to colistin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore, after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical antipseudomonal therapies and infection control measures in Spanish hospitals.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. (Pubmed Central) - Sep 13, 2020
KPC-28-producing E. coli isolates display an avibactam-resistant ESBL profile, which may be wrongly identified by molecular and immunochromatographic assays as the presence of a carbapenemase. Accordingly, confirmation of carbapenem hydrolysis will be mandatory with assays based solely on blaKPC gene or gene product detection.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019. (Pubmed Central) - Sep 13, 2020
The strains were sequence types (ST)s 258 and 147 and both harboured similar self-transmissible IncA/C2 plasmids encoding a novel Lys234Arg variant of the Vietnamese extended-spectrum β-lactamase (VEB)-1, not inhibited by AVI (VEB-25). Conjugal transfer of VEB-25-encoding plasmids to Escherichia coli yielded CAZ-AVI-resistant clones, supporting that VEB-25 is directly linked to the derived phenotype.
- ||| aztreonam / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical: What is the benefit of adding Avycaz to aztreonam for a stand-alone class B enzyme? I understand MBLs are often co-produced with ESBLs, KPCs, and other cephalosporinases, but in the absence of other b-lactamases on a molecular assay and reported susceptibility, what does it add? (Twitter) - Sep 11, 2020
- Fetroja (cefiderocol) / Shionogi
[VIRTUAL] in Vitro Antibacterial Activity of Cefiderocol Against Non-fermenter Clinical Strains Collected in North America and Europe from Multinational Surveillance Studies SIDERO-WT-20142018 (On Demand) - Sep 10, 2020 - Abstract #IDWeek2020IDWEEK_2583;
MICs for aztreonam-avibactam (ATM/AVI; ATM in the presence of 4 g/mL AVI), MVB, and SXT were determined only for SIDERO-WT 2018 strains... In 4 years of consecutive multinational surveillance studies, CFDC was the most active agent among antimicrobials tested against a wide range of NFGNB, including CarbNS strains.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] in Vitro selection Of enterobacter Cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanism (On Demand) - Sep 10, 2020 - Abstract #IDWeek2020IDWEEK_2445;
Despite the low MIC values of the mutant isolates for MER, the fold changes for this agent were higher than in FEP and CAZ-AVI. Resistance mechanisms in the mutants were complex.
- ciprofloxacin / Generic mfg., meropenem / Generic mfg., Daewon Pharmaceutical
[VIRTUAL] Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF) (On Demand) - Sep 10, 2020 - Abstract #IDWeek2020IDWEEK_2432;
Laboratories should be cautious of miE and ME that may occur with certain antibiotics. Furthermore, our observations suggest laboratories confirm CZA results for isolates with MICs near the breakpoint.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] evaluation of Synergy Testing Methods for Clinical Labs to Determine Susceptibility of Extensively Drug-resistant Gram-negatives to Ceftazidime/ Avibactam and Aztreonam Combination Therapy (On Demand) - Sep 10, 2020 - Abstract #IDWeek2020IDWEEK_2428;
SS and SX were reliable but prone to technical error. DS had the worst performance.
- | Preclinical, Journal: In vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents Against Cystic Fibrosis Respiratory Pathogens. (Pubmed Central) - Sep 1, 2020
Among the β-lactam-β-lactamase inhibitor agents, meropenem-vaborbactam had the greatest activity against Burkholderia and Achromobacter; including multi-drug-resistant and extensively-drug-resistant strains. None of the newer β-lactam-β-lactamase combination drugs showed increased activity compared to older agents against Stenotrophomonas maltophilia or Pandoraea spp.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Emergence of resistance to novel β-lactam β-lactamase inhibitor combinations due to horizontally-acquired AmpC (FOX-4) in ST308 Pseudomonas aeruginosa. (Pubmed Central) - Sep 1, 2020
None of the newer β-lactam-β-lactamase combination drugs showed increased activity compared to older agents against Stenotrophomonas maltophilia or Pandoraea spp. The growing prevalence of nosocomial infections produced by MDR and XDR P. aeruginosa strains is associated with significantly increased morbidity and mortality (1).….
- | Journal: Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. (Pubmed Central) - Sep 1, 2020
Data regarding the clinical efficacy of these new agents specific to infections caused by carbapenem-resistant pathogens are slowly emerging and appear to generally favor newer agents over previous best available therapy. As more treatment options become widely available for carbapenem-resistant gram-negative infections, the role of antimicrobial stewardship will become crucial in ensuring appropriate and rationale use of these new agents.
- || meropenem / Generic mfg., Daewon Pharmaceutical
Clinical, Journal: Antimicrobial Susceptibility and Virulence of mcr-1-Positive Enterobacteriaceae in China, a Multicenter Longitudinal Epidemiological Study. (Pubmed Central) - Aug 28, 2020
Most MPE isolates exhibited low-level colistin resistance. However, our study indicated that MPE isolates always carried a variety of drug resistance and virulence genes, which should be paid more attention.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Characterization of the IncX3 Plasmid Producing bla From Klebsiella pneumoniae ST34. (Pubmed Central) - Aug 28, 2020
The emergence of NDM-producing K. pneumoniae would be troublesome during treatment using ceftazidime-avibactam. Therefore, the rapid and accurate identification of carbapenemase-producing K. pneumoniae is necessary.
- | SYNERTAM (sulbactam Na+ampicillin) / KunWha Pharma, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. (Pubmed Central) - Aug 27, 2020
This study demonstrated that the sulbactam/avibactam combination displayed synergistic activity against A. baumannii isolates. This synergy was observed when both inhibitors were also used as part of the commercially available combinations: ampicillin-sulbactam and ceftazidime-avibactam.
- | aztreonam / Generic mfg., Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, north-eastern Germany, June to October 2019. (Pubmed Central) - Aug 23, 2020
Genomic analyses showed all isolates belonged to K. pneumoniae sequence type 307. Control measures and further investigations are ongoing.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Emergence of Hypervirulent Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae Isolates in a Chinese Tertiary Hospital. (Pubmed Central) - Aug 22, 2020
All nine isolates were considered to be CAZ/AVI-resistant hvKP according to the G. mellonella infection model and mouse lethality assay, with ST23 being the most common type (55.6%, 5/9). The newly emerged hypervirulent CAZ/AVI-resistant KP strain might cause a serious threat to public health, suggesting an urgent need for enhanced clinical awareness and epidemiologic surveillance.
- | meropenem / Generic mfg., Daewon Pharmaceutical
Journal: Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates. (Pubmed Central) - Aug 19, 2020
Non-ribosomal tobramycin-cyclam conjugate mitigates the effect of OprD/OprF porin loss in P. aeruginosa and potentiates β-lactam/β-lactamase inhibitors against carbapenem-resistant clinical isolates, highlighting the complexity of resistance to β-lactam antibiotics. Our strategy presents an avenue to further preserve the therapeutic utility of β-lactam antibiotics.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals. (Pubmed Central) - Aug 19, 2020
Our strategy presents an avenue to further preserve the therapeutic utility of β-lactam antibiotics. Resistance to ceftazidime/avibactam among P. aeruginosa clinical isolates has been shown to be a complex interplay of resistance mechanisms that can affect ceftazidime and/or avibactam and some similar findings were reported in laboratory isolates exposed to ceftazidime ± avibactam.